Faculty convened at an OncLive Scientific Interchange and Workshop to discuss HER2-mutant NSCLC testing, treatment selection, and sequencing strategies.
News|Videos|January 29, 2024
Inavolisib or Placebo in Combination With Palbociclib and Fulvestrant in Patients With PIK3CA Mutated, Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer: Phase III INAVO120 Primary Analysis
Author(s)Komal L. Jhaveri, MD, FACP
Komal L. Jhaveri, MD, FACP, presents key data on the addition of inavolisib to palbociclib and fulvestrant vs palbociclib and fulvestrant alone in select patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer.
Advertisement
Advertisement
Related to this article
OS in the LIVERATION trial of namodenoson in advanced HCC appeared longer than anticipated, prompting consideration of an earlier interim analysis.
Micvotabart pelidotin produced a 36% confirmed ORR and a 6.2-month median PFS in pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Patients with advanced abdominal cancers who are not candidates for tumor-removing surgery now have access to a treatment that may help control disease within the abdomen, reduce symptoms, preserve quality of life, and potentially extend survival.
The FDA approved sevabertinib for advanced or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations.
Dabogratinib led to a high rate of responses FGFR3-altered low-grade intermediate-risk non–muscle-invasive bladder cancer.
Mipletamig plus venetoclax and azacitidine produced a CBR of 93% in induction-ineligible, TP53-mutated acute myeloid leukemia.
A UCLA-led review found there is not yet enough real-world evidence to determine whether using AI in routine screening actually reduces the number of breast cancers diagnosed between screenings
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sevabertinib for Advanced HER2 TKD–Mutated Nonsquamous NSCLC
2
Micvotabart Pelidotin Monotherapy Yields Responses in Pretreated Recurrent/Metastatic HNSCC
3
TKD Mutation Status and CNS Data Guide Frontline Sequencing in HER2-Mutant NSCLC
4
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
5